ArticleThe clinical respiratory journal2025
Molecular Marker Discovery and Evaluation: EGF rs1897990 and rs1524106 Variants in a China Lung Adenocarcinoma Young Population.
Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Marker Discovery and Evaluation: EGF rs1897990 and rs1524106 Variants in a China Lung Adenocarcinoma Young Population.The clinical respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe objective of this study is to investigate the genetic susceptibility and risk factors of EGF gene rs1897990 and rs1524106 in lung adenocarcinoma young patients aged ≤ 45 years.
methodsA case-control study was conducted. DNA was extracted and identified from 88 samples from case and control groups by single-nucleotide polymorphism assay. PCR amplification was performed by TaqMan probe method, and the factors of smoking, drinking, sex, and age were also included. To investigate the clinical factors and genotyping differences between case and control groups.
resultsSmoking was an influential factor in young lung adenocarcinoma patients. The mutation frequency of EGF gene rs1897990 CT heterozygous mutant was different between the two groups (p = 0.021). The T alleles of EGF rs1897990 and rs1524106 were significantly different between the two groups (p = 0.034 and p = 0.023).
conclusionsThe young lung adenocarcinoma population (≤ 45 years old) is susceptible to EGF rs1897990 and rs1524106 variants, with smoking being another risk factor. Additionally, smoking may enhance the risk of EGF rs1897990 and rs1524106 variants threatening the development of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.